FOLH1 and prostate carcinoma: As shown by the phase III VISION trial (NCT03511664), PSMA-617 labeled with the theranostic radionuclide 177Lu leads to a significant reduction in bone- and lymph node metastases and increased the survival rate when applied in combination with standard-of-care therapies, which finally led to its approval thus far for patients with advanced prostate cancer [8,9,10,11].